Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations
Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations
批准号:
10255409
负责人:
Steven Isaacman
金额:
$39.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-05-01 至 2022-10-31
关键词:
AddressAffinityAmericanBathingBiological SciencesBiomassCarbonChemistryCreamCutaneousDevelopmentDiagnosisEcosystemElastomersEstheticsEuropeExcipientsExcisionFloridaGoalsHealthcareHomeHumanImmersionIncidenceInternationalKnowledgeLabelLinkMalignant NeoplasmsManufacturer NameMarket ResearchMediatingMissionModelingNational Cancer InstituteOutcomePerformancePhasePhototoxicityPlantsPreventive measureProcessPropertyRegulationResearch SupportResistanceRiskRisk FactorsSafetySalesSilicone ElastomersSkinSkin CancerSmall Business Innovation Research GrantStatutes and LawsSun protection factorSunlightSunscreening AgentsSwimmingTechnologyTimeToxic effectTubeUV Radiation ExposureUV protectionUltraviolet RaysUnited StatesUnited States Food and Drug AdministrationWaterbasebiodegradable polymerbiomaterial compatibilitycancer careclinical developmentcommercial applicationconsumer demanddesignfallsglobal environmenthealthy volunteerimprovednovelphotoprotectionpreventsensorskin organogenesissuccesstechnological innovationultraviolet damagevolunteer
中文摘要
项目总结/摘要
待解决的问题及意义:紫外线辐射(UVR)暴露是一个危险因素,
皮肤癌的发展,卫生保健机构建议使用防晒霜作为预防措施,
measure.美国和国际上最近的立法已经禁止销售成分,
这是防水防晒霜的基础,迫切需要新产品来满足现有和
新兴立法。
产品和长期目标:本SBIR的产品将是完全生物相容的SPF 30广谱
防晒霜,以6盎司管出售,符合FDA的标准,被标记为“防水(80分钟)”,
基于Nanometics(D.B.A.)PHD Biosciences [PHD])专有弹性体技术。成功
这种防晒产品的开发直接解决了国家癌症研究所的使命,
提高对紫外线辐射的防护,降低患皮肤癌的风险。
技术创新:PHD防晒霜采用了PHD专有的可生物降解弹性体
技术,这是第一个植物衍生的弹性体局部产品,提供防水,
与所有食品和药物管理局批准的紫外线过滤器兼容,并概括了有利的美学
有机硅弹性体的性能。
具体目标#1。证明PHD防晒霜在健康情况下至少防水80分钟
志愿者本目标研究将在FDA指导下进行,并将证明以下可行性:
在水中连续浸泡80分钟后,PHD防晒剂耐用水除去。成功
标准:如果浸水80分钟后,平均SPF值福尔斯在一个标准范围内,则该目标成功
预浸SPF的偏差为30。
商业机会:到2023年,全球防晒霜市场预计将超过25亿美元。初级
二级市场研究支持PHD防晒霜的需求,以满足新兴的需求,
通过新的立法。II期SBIR研究将包括额外的研究,以确认大量
志愿者;将性能与领先的商业防晒霜进行比较;并优化化学,
生产和控制(CMC)工艺,以商业规模生产产品。
英文摘要
PROJECT SUMMARY / ABSTRACT
Problem to be Solved and Significance: Exposure to Ultraviolet radiation (UVR) is a risk factor for the
development of skin cancer, and health care agencies recommend that sunscreens be used as a preventative
measure. Recent legislation in the U.S. and internationally has banned the sale of ingredients that are
fundamental to water-resistant sunscreens, creating an urgent need for new products that satisfy existing and
emerging legislation.
Product and Long-Term Goal: The product of this SBIR will be a wholly biocompatible SPF 30 broad spectrum
sunscreen cream, sold in 6-oz tubes, that satisfies FDA’s criteria to be labeled as ‘Water Resistant (80 min)’ and
is based on the Nanometics (d.b.a. PHD Biosciences [PHD]) proprietary elastomer technology. Successful
development of this sunscreen product directly addresses the mission of the National Cancer Institute by
improving protection against UVR and decreasing the risk of skin cancer.
Technological Innovation: The PHD sunscreen incorporates PHD’s proprietary biodegradable elastomer
technology, which is the first plant derived elastomer for topical products that provides water resistance, is
compatible with all Food and Drug Administration approved UV filters, and recapitulates the favorable aesthetic
properties of silicone elastomers.
Specific Aim #1. To demonstrate that the PHD Sunscreen is water resistant for at least 80 min on healthy
volunteers. Studies in this Aim will be conducted under FDA guidance and will demonstrate the feasibility that
the PHD sunscreen is resistant to removal with water after 80 min of continuous immersion in water. Success
Criterion: This Aim will be successful if after 80 min of water immersion, the mean SPF falls within one standard
deviation of the pre-immersion SPF of 30.
Commercial Opportunity: The global sunscreen market is projected to exceed $2.5 billion by 2023. Primary
and secondary market research supports the need for the PHD Sunscreen to meet the emerging needs created
by new legislation. Phase II SBIR studies will include additional studies to confirm safety on a larger number of
volunteers; compare performance to leading commercial sunscreens; and optimize the chemistry,
manufacturing, and control (CMC) processes to produce the product at commercial scale.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
-
批准号:10820810
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2023
-
负责人:Steven Isaacman
-
依托单位:
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer
-
批准号:10080275
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:Steven Isaacman
-
依托单位:
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer
-
批准号:10202504
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:Steven Isaacman
-
依托单位:
A targeted immunomodulator for the treatment of acute sickle crisis
-
批准号:8979976
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2015
-
负责人:Steven Isaacman
-
依托单位:
Orally available transition state inhibitors for triple negative breast cancer
-
批准号:8646623
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:Steven Isaacman
-
依托单位:
Schiff base forming sunscreen filters for long-wear UV protection
-
批准号:8833063
-
项目类别:
-
资助金额:$75.0万
-
财政年份:2012
-
负责人:Steven Isaacman
-
依托单位:
Schiff base forming sunscreen filters for long-wear UV protection
-
批准号:8392787
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2012
-
负责人:Steven Isaacman
-
依托单位:
海外基金